ScoreWhy is Concord Drugs Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 5.41%
- Poor long term growth as Net Sales has grown by an annual rate of 14.78% and Operating profit at 2.53% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.56
2
With a growth in Net Profit of 1225%, the company declared Very Positive results in Mar 26
- PBT LESS OI(Q) Highest at Rs 0.75 cr.
- PAT(Q) Highest at Rs 0.53 cr.
- NET SALES(Q) Highest at Rs 37.90 cr
3
With ROCE of 5.2, it has a Attractive valuation with a 2 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 151.59%, its profits have risen by 72% ; the PEG ratio of the company is 0.8
4
Majority shareholders : Promoters
5
Market Beating performance in long term as well as near term
- Along with generating 151.59% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Concord Drugs should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Concord Drugs for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Concord Drugs
151.59%
2.77
54.66%
Sensex
-10.21%
-0.78
13.06%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
14.78%
EBIT Growth (5y)
2.53%
EBIT to Interest (avg)
1.56
Debt to EBITDA (avg)
5.56
Net Debt to Equity (avg)
0.26
Sales to Capital Employed (avg)
0.90
Tax Ratio
28.38%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.64%
ROE (avg)
1.92%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
102
Industry P/E
34
Price to Book Value
2.23
EV to EBIT
37.90
EV to EBITDA
26.51
EV to Capital Employed
1.97
EV to Sales
1.53
PEG Ratio
0.75
Dividend Yield
NA
ROCE (Latest)
5.20%
ROE (Latest)
2.18%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend25What is working for the Company
PBT LESS OI(Q)
Highest at Rs 0.75 cr.
PAT(Q)
Highest at Rs 0.53 cr.
NET SALES(Q)
Highest at Rs 37.90 cr
PBDIT(Q)
Highest at Rs 1.49 cr.
EPS(Q)
Highest at Rs 0.40
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Concord Drugs
Net Sales - Quarterly
At Rs 37.90 cr has Grown at 264.77%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 0.75 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 0.53 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 37.90 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 1.49 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 0.40
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
